Minimal expansion of the GCG repeat in the PABP2 gene does not predispose to sporadic inclusion body myositis
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Sporadic inclusion body myositis (IBM) is one of the most common acquired muscle diseases of adults. Usually, IBM presents in patients over 50 years of age with slowly progressive proximal muscle weakness, distal muscle weakness, or both, with characteristic early involvement of the long finger flexor muscles.1 Pathologically, IBM muscle shows rimmed vacuoles and characteristic nuclear or cytoplasmic 15- to 18-nm–diameter tubulofilamentous inclusions.
We have observed that some oculopharyngeal muscular dystrophy (OPMD) patients, after a long duration of disease (15 to 20 years), manifest limb weakness similar to that seen in IBM. In such cases, muscle biopsies also show rimmed vacuoles and inclusions that consist not only of the specific 8.5-nm–diameter intranuclear filaments of Tomé, but also the IBM type 15- to 18-nm tubulofilaments.2 These common features in OPMD and sporadic IBM raised the possibility that they share certain etiologic factors, even though the entities show substantially different characteristics. The mutations responsible for OPMD have recently been identified as a short GCG expansion in the poly (A) binding protein 2 gene (PABP2) on chromosome 14.3 In …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David Beversdorf and Dr. Ryan Townley
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBMNizar Chahin, Andrew G. Engel et al.Neurology, September 19, 2007 -
Articles
Aberrant expression of cyclin-dependent kinase 5 in inclusion body myositisS. Nakano, I. Akiguchi, S. Nakamura et al.Neurology, November 01, 1999 -
Articles
RNA interference as potential therapy for neurodegenerative diseaseApplications to inclusion-body myositis?Henry Paulson et al.Neurology, December 16, 2005 -
Articles
Messenger RNA degradation may be inhibited in sporadic inclusion body myositisS. Nakano, A. Shinde, H. Ito et al.Neurology, August 08, 2005